China-US Divide Deepens On Covid Vaccines, Azar Taiwan Visit
CanSino to Start Vaccine Trial in Mexico
China has shown willingness to go tit-for-tat in its bilateral disputes with the US and the latest comments from US officials show an underlying distrust over clinical data and vaccines safety in China, raising fresh concerns just when collaboration is needed to accelerate availability of the first vaccines in the global pandemic.
You may also be interested in...
The UK has been stepping up its COVID-19 activity in recent days, ordering more vaccines, encouraging more volunteers to join clinical trials, and expanding its RECOVERY platform for potential new coronavirus therapies. But the government's sudden decision to replace Public Health England with a new institute has raised some concerns within the biopharma industry.
The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October.
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.